Skip to main content

Table 6 Multivariate analysis of patient baseline characteristics for the effect of interaction with axitinib titration on OS

From: Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

Parameter HR for Covariate
Placebo Titration Axitinib Titration
Metastatic site (≥3 vs. ≤2) 2.191 4.438
Time from histopathological diagnosis to treatment (< 1 vs. ≥1 year) 1.437 3.569
Baseline Hb < LLN (yes vs. no) 0.940 3.378
  1. Abbreviations: CI confidence interval, Hb haemoglobin, HR hazard ratio, LLN lower limit of normal